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BPA exposureBisphenol A (BPA) is a component of polycarbonate plastics and epoxy resins used in many commercial
products including coatings and liners of food containers. Low levels of BPA can be detected in over 90% of
human urine samples in the US, indicating that exposure to BPA is widespread. In 2008, the US National
Toxicology Program’s Center for the Evaluation of Risks to Human Reproduction (NTP-CERHR) expressed
concerns regarding BPA’s potential health effects, and suggested improved study designs and methodol-
ogies that they believed would address those concerns. This paper discusses some of the controversial
issues surrounding BPA, summarizes the current regulatory status of BPA, reviews recent pharmacoki-
netic studies, and describes ongoing and planned research on the effects of BPA. In addition, we evaluate
two papers studying BPA neurobehavioral effects, identiﬁed by the European Food Safety Authority and
the German Federal Institute for Risk Assessment as being valid for use in risk assessment, to determine
whether they address the NTP-CERHR methodological concerns. The data from these studies would likely
be sufﬁcient for NTP to lower its concern level for neurobehavioral effects of BPA. At this time, many reg-
ulatory agencies from around the world support the use of BPA in food contact materials.
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In recent years, bisphenol A (BPA), a component of plastics and
coatings used for food storage, has received considerable attention
regarding the potential for adverse health effects, much of which
stems from the fact that is has been shown to have weak estro-
genic-like effects (Matthews et al., 2001). Studies using laboratory
animal models, when well-conducted by well-accepted standards,
can provide valuable information for use in safety assessments to
predict potential toxicity in humans. However, discrepancies in
outcomes among and between studies with BPA, in particular be-
tween standard guideline studies on one side and a large number
of small scale in vitro and in vivo research or experimental studies
addressing novel endpoints on the other side, has often led to
controversy.
In 2008, the National Toxicology Program’s (NTP) Center for
Evaluation of Risk to Human Reproduction (CERHR) reviewed the
scientiﬁc literature on BPA and published their ﬁndings regarding
health effects in a NTP-CERHR Monograph on BPA (NTP, 2008).
NTP-CERHR scored their ﬁndings as ‘‘Negligible Concern’’, ‘‘Mini-
mal Concern’’, ‘‘Some Concern’’, ‘‘Concern’’ and ‘‘Serious Concern’’.
The NTP’s report found that there was ‘‘Some Concern’’ for BPA ef-
fects on the brain, behavior, and prostate gland in fetuses, infants,
and children at current human exposures. The NTP report also
found ‘‘Minimal Concern’’ for BPA effects on mammary gland, early
age for puberty for females in fetuses, infants and children, or for
workers exposed to higher levels in occupational settings; and
‘‘Negligible Concern’’ that BPA exposure to pregnant women will
result in neonatal mortality, birth defects or reduced birth weight
and growth in offspring, or will cause reproductive effects in non-
occupationally exposed adults. NTP stated that for areas of ‘‘Some
Concern’’, additional research is needed to ﬁll scientiﬁc data gaps,
and recommended improved study designs and methodologies to
facilitate published research utility for future BPA health effects
assessments.
Since the publication of the NTP-CERHR monograph, hundreds
of scientiﬁc studies have been published on the health effects of
BPA, including studies that address the additional research identi-
ﬁed by NTP in the areas of ‘‘Some Concern’’. This paper discusses
some of the controversial issues surrounding BPA, summarizes
the current regulatory status of BPA, reviews recent pharmacoki-
netic studies, and describes ongoing and planned research on the
effects of BPA. In addition, we evaluate two papers studying BPA
neurobehavioral effects, identiﬁed by the European Food Safety
Authority (EFSA) and the German Federal Institute for Risk Assess-
ment (BfR) as being valid for use in risk assessment, to determine
whether they address the NTP-CERHR suggestions for study de-
signs and methodologies.1.1. Uses of Bisphenol A
BPA monomer (aglycone) is an industrial chemical used to
make polycarbonate plastic, a lightweight, high-performance
plastic, and epoxy resins, some of which are used to coat surfaces
of food containers. Examples include wine storage tanks, food
transport vehicles, and metal cans containing processed foods
and beverages. BPA-containing resin coatings have been used by
the food and beverage industry for over 50 years; they providean effective barrier preventing chemical reactions between the
food and the metal, thereby enhancing shelf life and food safety.
Manufactured products containing BPA have other specialized
uses, such as in ﬂame-retardant materials, special plastics used
in medical devices and medical adhesives and dental prosthetics
and sealants. There is a large scientiﬁc database assessing the
safety of BPA, making it one of the most thoroughly studied
materials approved for food contact use. While there is continued
effort by the food and canning industry to ﬁnd an effective and
safe alternative, at this time there is no known practical and safe
alternative to BPA-containing epoxy resin coatings for the myriad
of food products packaged.2. Bisphenol A exposure
BPA may be present in small quantities as unreactive monomer
in some materials, and may leach from some food contact sub-
stances and polycarbonate products as the material ages or is ex-
posed to harsh chemicals such as dish washing detergents or is
exposed to UV radiation. The US Centers for Disease Control and
Prevention (CDC) identiﬁed BPA (as the inactive conjugate metab-
olite) in 93% of urine samples obtained as part of the National
Health and Nutrition Examination Survey (NHANES) from over
2460 people, suggesting that BPA exposure is widespread (Calafat,
2011). The geometric mean urine concentration was calculated to
be 1.9 lg BPA/l, when normalized for creatinine concentration
(CDC, 2012). In 2011, Lakind and Naiman estimated the mean daily
BPA intake from all sources in the US population age 6–60 ranged
from 0.03 to 0.05 lg/kg body weight (bw) (Lakind and Naiman,
2011). The World Health Organization (WHO) estimated the mean
BPA exposure for adults ranged from less than 0.01 to 0.40 lg/
kg bw/day (95th percentile 0.06–1.5 lg/kg bw/day) and for young
children to teenagers was 0.1–0.5 lg/kg bw/day (95th percentile
0.3–1.1 lg/kg bw/day) (WHO, 2011).
Health Canada recently decreased its probabilistic estimate of
dietary exposure to BPA, and determined that the general popula-
tion has a mean BPA exposure of 0.055 lg/kg bw/day and that
children age 0–18 months had exposures ranging from 0.083 to
0.164 lg/kg bw/day (Health Canada, 2012). The Canadian Total
Diet Study estimated a BPA intake of 0.075 lg/kg bw/day for all
Canadians and a maximum BPA intake in children less than
1 month of age of 0.33 lg/kg bw/day (Cao et al., 2011). The US
Food and Drug Administration (FDA) estimates that BPA exposure
from use in food contact materials in infants and adults is
2.42 lg/kg bw/day and 0.185 lg/kg bw/day, respectively. For
comparison, the FDA has determined the appropriate No-Ob-
served-Adverse-Effect Level (NOAEL) for BPA to be 5 mg/kg bw/
day (5000 lg/kg bw/day); the NOAEL for systemic toxicity is de-
rived from two multigenerational rat studies (FDA, 2008). This
is approximately 2000 and 27,000 times higher than the FDA esti-
mates of BPA intake from food contact materials for infants and
adults, respectively.
The US Environmental Protection Agency (USEPA) has set a
chronic oral Reference Dose (RfD) for BPA of 50 lg/kg bw/day
(USEPA, 2012a). The RfD is deﬁned as ‘‘An estimate (with uncer-
tainty spanning perhaps an order of magnitude) of a daily oral
exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious effects
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Authority (EFSA) has set a Tolerable Daily Intake (TDI) for BPA of
50 lg/kg bw/day (EFSA, 2010). The TDI is deﬁned as ‘‘an estimate
of the quantity of a chemical contaminant to which we may be
exposed through environmental contamination, and which when
found in food can be ingested daily over a lifetime without posing
a signiﬁcant risk to health’’ (EFSA, 2012). Both the RfD and the TDI
are approximately 100 times higher than the 95th percentile BPA
intake level for adults of 1.5 lg/kg bw/day, estimated by WHO
(2011) and approximately 20 times the FDA estimation of the
BPA intake in infants .
There is a general consensus that effects on children should be
evaluated carefully, even when exposed to compounds that may
pose little if any risk to adults, due to children’ rapidly developing
organ systems, and metabolic and digestive differences. FDA notes
that children have unique health and developmental characteris-
tics that may affect how they respond to various food and medical
products. Through research both within and outside FDA, there are
many studies being conducted that assess how therapeutics and
food substances behave in adults and children (FDA, 2010). FDA’s
National Center for Toxicological Research (NCTR), in partnership
with the National Institutes for Environmental Health Sciences
(NIEHS) and NTP, has been investigating the potential differences
between fetal, neonatal, juvenile and adult mice, rats and non-hu-
man primates (NHP) exposed to BPA. Recent pharmacokinetic
studies in this area are summarized in Section 9.1.3. Current regulatory status and assessments of authoritative
scientiﬁc organizations
Numerous regulatory agencies and authoritative scientiﬁc
bodies around the world have conducted and published health
assessments regarding exposure to BPA from food packaging mate-
rials, baby bottles and sippy cups made of polycarbonate plastic
and exposure from other sources. For example, the EFSA conducted
a comprehensive review of over 800 new literature citations and
published their ﬁndings in September, 2010; EFSA’s conclusion
was that there was no reason to change the established Tolerable
Daily Intake (TDI) of 50 lg/kg bw/day lifetime (EFSA, 2010). A UN
joint Food and Agriculture Organization (FAO)/World Health Orga-
nization (WHO) Expert Meeting reviewed over 100 key literature
citations and published their ﬁndings. They concluded that ‘‘Con-
tinued research into the toxicokinetics of BPA and its estrogenic
and other mechanisms of action will be needed before it is possible
to determine the appropriate points of departure (e.g. NOAEL,
LOAEL, benchmark dose) for human risk assessment with conﬁ-
dence’’ (WHO, 2011).
The FDA has conducted several in depth reviews of BPA expo-
sure and risk as a result of exposure from food contact materials.
FDA has determined the appropriate NOAEL for its assessment of
BPA to be the NOAEL for systemic toxicity of 5 mg/kg bw/day
(5000 lg/kg bw/day) derived from two multigenerational rodent
studies. FDA states ‘‘FDA is not recommending that families change
the use of infant formula or foods, as the beneﬁt of a stable source
of good nutrition outweighs the potential risk from BPA exposure’’
(FDA, 2012a). However, FDA is continuing its research and moni-
toring of studies to address uncertainties raised about BPA.
The Advisory Committee of the German Society of Toxicology
evaluated the scientiﬁc literature and concluded that the ‘‘current
Tolerable Daily Intake (TDI) [50 lg/kg bw/day] for BPA is ade-
quately justiﬁed and that the available evidence indicates that
BPA exposure represents no noteworthy risk to the health of the
human population, including newborns and babies’’ (Hengstler
et al., 2011). In addition, the Japanese National Institute of Ad-
vanced Industrial Science and Technology (AIST) concluded thatthe risk of BPA to human health is believed to ‘‘be very small’’ (Ja-
pan AIST, 2011), and Health Canada recently concluded ‘‘Therefore,
based on the overall weight of evidence, the ﬁndings of the previ-
ous assessment remain unchanged and Health Canada’s Food
Directorate continues to conclude that current dietary exposure
to BPA through food packaging uses is not expected to pose a
health risk to the general population, including newborns and
young children. This conclusion is consistent with those of other
food regulatory agencies in other countries, including notably the
United States, the European Union and Japan’’.
Consumers remain concerned about exposures in infants and
children, due to the suggestion of developmental effects in some
animal studies. In 2011, the American Chemistry Council requested
that the FDA ‘‘remove infant feeding bottles (‘‘baby bottles’’) and
spill-proof cups designed to help train babies to drink from cups
(‘‘sippy cups’’) from the scope of permitted food contact applica-
tions for polycarbonate resins. This request was ‘‘based solely on
the grounds that these uses have been intentionally and perma-
nently abandoned by all major product manufacturers’’ (ACC,
2011). In 2012, the FDA responded by amending the food contact
regulations, based solely on abandonment, by removing BPA man-
ufactured baby bottles and sippy cups from approved food contact
substances (FDA, 2012b). In early 2011 the European Commission
issued a new Directive setting a temporary ban on the use of BPA
in the manufacture and placing on the market of polycarbonate in-
fant feeding bottles in Europe (European Commission, 2011).
France has a ban on BPA in baby bottles, and has introduced legis-
lation that would ban use of BPA for materials in contact with food
for children 0–3 years of age in 2013. The Danish Veterinary and
Food Administration banned BPA in food containers and products
for very young children effective July 1, 2010. The Australian gov-
ernment has instituted a voluntary phase-out of polycarbonate
baby bottles (FSANZ, 2012).
See Supplemental Table 1 for statements and conclusions from
several regulatory agencies and authoritative scientiﬁc organiza-
tions regarding BPA in food packaging materials. At this time, USF-
DA, EFSA, BfR, FDA, German Society of Toxicology, Health Canada
and the Japanese AIST Australia/New Zealand support the use of
BPA in food contact materials.4. Overview of the Weight of Evidence approach in evaluating
the scientiﬁc literature
Generally, regulatory agencies and risk assessment scientists
evaluate scientiﬁc studies using a Weight of Evidence (WOE) ap-
proach. This approach uses the results found in multiple, high qual-
ity studies as the basis for determining effects. Single studies, or
studies with methodological or study design deﬁciencies, are con-
sidered, but the results are usually given less weight.
As an example, a WOE methodology was published by Klimisch
et al. (1997), in which studies are assigned to one of four
categories:
1. Reliable without restriction (i.e., conforming to good labora-
tory practices (GLP) or some other set of quality criteria)
2. Reliable with restriction (i.e., well documented and scientif-
ically acceptable, but falling short of GLP)
3. Not reliable (not well documented or used unacceptable
methods)
4. Not assignable (e.g., abstracts)
Evidence that is considered ‘‘not reliable’’ may be used to an ex-
tent on a case-by-case basis, depending on the expertise of the
evaluators. McCarty et al. (2012) have proposed a six step scheme
for regulatory peer review that derives a numerical score and
Table 1
NTP concerns regarding study design and methodology.
Appropriate route of exposure (i.e., one that is relevant to human oral
exposure)
Animals studied for an appropriate length of time
Adequate number of animals
Use of appropriate or recognized animal model
Appropriate statistical analysis (including use of the litter as the
experimental unit, rather than the pup, to control for litter effects)
Were differences in metabolism, pharmacokinetics and pharmacodynamics
between humans and animals taken into account?
Did the researchers take steps to eliminate BPA from their analytical
equipment?
Did the study evaluate dose–response?
Are the conclusions appropriate to the study design (i.e., are conclusions
overly broad?)
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the WOE evaluation process, including key assumptions, uncer-
tainties, and any adjustments or reﬁnements in weighting factors
required subsequent to their initial formulation.
WOE is widely used by scientists in the evaluation of scientiﬁc
data and in setting regulations and establishing guidelines in the
public health policy sphere. For example, the USEPA applies a
WOE approach to carcinogen risk assessment (USEPA, 2005). Such
evaluations rely on scientiﬁc consensus, which is essential for reg-
ulatory integrity and expert judgment when reaching ﬁnal conclu-
sions (Lorentzen and Hattan, 2010). Regulators can then determine
if the WOE does or does not support the safety of an agent, deter-
mine if more research is required, and establish a set of uncertain-
ties around a decision.NTP (2008).5. Comparison of research and guideline-compliant studies
Studies used to evaluate safety, or the probability of harm to
humans, must be of high quality; often this means that studies
must be guideline-compliant; i.e., follow FDA or Organisation for
Economic Co-operation and Development (OECD) Good laboratory
Practice guidelines (GLP). The US Code of Federal Regulations (CFR)
Title 21, Subchapter A, Part 58: Good Laboratory Practice for Non-
clinical Laboratory Studies, was established in 1978 by the US Food
and Drug Administration. Its creation was driven by in-depth
investigations of 40 contract and/or research laboratories across
the US that identiﬁed fraudulent activities in some laboratories
and very poor laboratory practices in most. ‘‘GLP embodies a set
of principles that provides a framework within which laboratory
studies are planned, performed, monitored, reported and archi-
ved.’’(MHRA, 2012). GLP assures that the data submitted to FDA
are a true reﬂection of the study outcome and that the data are
traceable and can be reviewed by the regulatory evaluators. More-
over, it assures that protocols are designed and data interpreted
such that the chance for investigator bias is minimized. GLP is
the international set of standards required by global regulatory
bodies reviewing a sponsor’s non-clinical laboratory study submis-
sions or in establishing product safety.
Regulatory agencies thus generally expect that most animal
studies that are used in support of a sponsor’s submission to regu-
latory authorities should follow GLP guidelines; even most analyt-
ical procedures and in vitro studies used in support of animal
studies or conducted independently should follow GLP. However,
as previously noted, a balanced and objective risk assessment is a
comprehensive process that relies onWOE to consider all the avail-
able data. While FDA/OECD guideline compliance plays a major
role when considering data for regulatory decision making, other
criteria are considered when judging the validity and regulatory
utility of data (e.g. sample size, statistical analysis, reproducibility,
dose–response, potential for background contamination, adequate
reporting, availability of raw data, etc.) and that non-compliance
with GLP criteria alone is not sufﬁcient for a risk assessor to inval-
idate and dismiss a study (see Table 1).
There remains signiﬁcant controversy regarding protocol design
and the research environment where BPA studies are conducted.
Many small scale research and exploratory studies designed to
show potential adverse outcomes for BPA are conducted in aca-
demic institutions, which generally do not have the physical or
ﬁnancial resources to conduct GLP or guideline compliant studies.
Studies conducted following FDA or OECD Good Laboratory Prac-
tice (GLP) guidelines generally take years to conduct and cost mil-
lions of dollars. In contrast, academic or experimental research
studies are generally conducted in months, do not follow GLP
guidelines, and may use unique or novel protocol designs. Also,
the studies may use a limited number of animals and use dosesor routes of administration not applicable to human exposure.
Rarely are raw data made available for review.6. Laboratory analytical concerns
BPA has numerous uses and can be found in products used in
virtually every room in homes, hospitals, schools, and ofﬁce build-
ings. It is also widespread in research laboratories and animal
rooms (Markham et al., 2010; Twaddle et al., 2010). Many labora-
tories use polycarbonate animal cages, and plastic items are used
extensively in research laboratories and laboratory equipment,
even in equipment that is utilized to measure BPA. Therefore,
researchers must take deliberate and extensive measures to con-
trol for BPA contamination. An alternative approach is to use sta-
ble-isotope labeled BPA (e.g., d6-BPA) to control for BPA
contamination (Doerge et al., 2011a; Twaddle et al., 2010; Ye
et al., in press). BPA analysis requires the use of highly sensitive
equipment (e.g., LC/MS/MS system) and methodology that has
been validated (internal standards) to measure both the conju-
gated and aglycone BPA. Adherence to these methodologies is re-
quired to produce valid and reproducible results when analyzing
BPA in biological samples.7. Overview of cooperative studies between NTP/FDA and NIEHS
extramural grantees
To help resolve differences between studies following tradi-
tional GLP guidelines and studies conducted in research laborato-
ries using new (non-traditional) endpoints and methods, the NTP
and the FDA’s National Center for Toxicological Research (NCTR)
are collaborating with the National Institute of Environmental
Health Sciences (NIEHS) Division of Extramural Research and
Training (DERT) to foster collaboration between federal and aca-
demic scientists. These studies are being conducted at NCTR with
an FDA scientist serving as the Principal Investigator. The goal of
the collaboration is to use a two year chronic study design for
BPA, conducted under FDA’s GLP guidelines, as the core study,
and then at various times, designated animals or animal tissues
will be distributed to grantees from research laboratories for fur-
ther testing and analysis.
Twelve academic researchers have received NIEHS funding for
this BPA project. The core study will assess traditional toxicology
endpoints, such as cancer; other arms of the study will assess addi-
tional endpoints, typically not measured in GLP guideline studies,
with the intent to provide the grantees with animals and tissues
from a GLP guideline study. The investigators are: Nira Ben-
Jonathan, Ph.D., University of Cincinnati – Metabolism and
heart disease, Kim Boekelheide, M.D., Ph.D., Brown University –
Male reproduction, Jodi Flaws, Ph.D., University of Illinois at
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Gonzalez-Cadavid, Ph.D., Los Angeles Biomedical Research Insti-
tute at Harbor-UCLA Medical Center – Male reproduction, Andrew
Greenberg, Ph.D., Tufts University – Metabolic disease and diabe-
tes, Shuk-Mei Ho, Ph.D., University of Cincinnati – Cancer, Norbert
Kaminski, Ph.D., Michigan State University – Immunity, Heather
Patisaul, Ph.D., North Carolina State University – Neurobehavior,
Gail Prins, Ph.D., University of Illinois at Chicago – Prostate cancer,
Ana Soto, M.D., Tufts University – Mammary cancer, Frederick vom
Saal, Ph.D., University of Missouri – Reproductive development and
Robert Zoeller, Ph.D., University of Massachusetts, Amherst – Brain
and thyroid function.
Animals were allocated to the study in August, 2012 and dosing
has begun. The core study will include a one year interim sacriﬁce
and a two year sacriﬁce with complete gross and micropathology
assessment. The test system includes Sprague–Dawley rats from
NCTR’s animal colony, a soy-free diet, gavage of dams fromgestation
day 6 (GD6) until parturition, then direct dosing of pups from post
natal day 1 (PND1). Half of the animals will be dosed continuously
for two years and half will have dosing stopped at PND 21. The dose
groups will be vehicle, 2.5, 25, 250, 2500, and 25,000 lg/kg bw/day
BPA. There will be two ethinyl estradiol ‘‘positive’’ control groups,
0.05 and 0.5 lg/kg bw/day. Littermates from the core studywill pro-
vide animals and tissues for the NIEHS-funded grantees, including a
behavior study. Not all of the grantees will use all dose groups or
both the continuous and stopdose animals. Animals and tissues pro-
vided to the grantees will be blinded as to dose groups. Once the
grantees studies are complete and the code unlocked, they are free
to publish the results without further NTP or FDA review. The core
study is expected to take 4–5 years to complete; grantee studies
may be completed in a shorter time (Birnbaum et al., 2012).8. Overview of NTP-CERHR ﬁndings and requests for further
research
The NTP is a Department of Health and Human Services
(DHHSs) Interagency Program established to coordinate toxicology
research and testing, strengthen the science base in toxicology, de-
velop and validate improved testing methods, and provide infor-
mation about potentially toxic chemicals to health regulatory
and research agencies, scientiﬁc and medical communities and
the public. The Center for Evaluation of Risk for Human Reproduc-
tion (CERHR, currently called Ofﬁce of Health Assessment and
Translation (OHAT) is part of the NTP. CERHR/OHAT expert scien-
tiﬁc panels evaluate evidence regarding chemicals of public health
concern and provide assessments of potential health effects.
Concerns for the safety of BPA and the contradictory ﬁndings
regarding BPA health effects published in the scientiﬁc literature
prompted NTP-CERHR to establish an Expert Scientiﬁc Panel (Pa-
nel) in 2007 to conduct a comprehensive review of BPA using all
resources available, including the scientiﬁc literature to date
(NTP-CERHR, 2007). In 2008, the CERHR Expert Scientiﬁc Panel re-
ported that there were no data on the effects of human develop-
mental exposure to BPA available (at the time of the Panel’s
review) and thus no conclusions were made about risk to humans
(Chapin et al., 2008). The Panel went onto summarize their ﬁnd-
ings, based only on animal studies, as: For pregnant women and fe-
tuses: Some Concern for neural and behavioral effects; Minimal
Concern for prostate effects; Minimal Concern for accelerated pub-
erty; Negligible Concern for birth defects; For Infants and Children:
Some Concern for neural and behavioral effects; Minimal Concern
for accelerated puberty effects; For Adults (based on animal stud-
ies): Negligible Concern for adverse reproductive effects in the gen-
eral population; and Minimal Concern for occupationally exposed
populations (Chapin et al., 2008).It is important tonote that in thePanel’swrittenconclusions, they
stated ‘‘while the panel did not necessarily expect a speciﬁc effect to
display a monotonic dose response (e.g. consistently increasing or-
gansize),manymembersof thepanel expected thehighdose studies
with bisphenol A to detect some manifestation of toxicity (e.g., al-
tered weight, histopathology) in tissues reported to be affected at
lowdoses even if the study could not replicate the reported lowdose
effect’’. The Panel alsonoted ‘‘There are several large, robust,well de-
signed studieswithmultipledosegroupsusing several strainsof rats
and mice and none of these detected any adverse reproductive ef-
fects at low to moderate dosage levels of BPA administered via the
relevant route of human exposures. Further, none of these studies
detected changes in prostate weight, age at puberty (rat), pathology
or tumors in any tissue, or reproductive tractmalformations. For this
reason, Panel members gave more weight to studies that evaluated
both low-andhigh-doses of bisphenol A compared to low-dose-only
studies in caseswhere the target tissueswere comparably assessed’’.
The written conclusions also note ‘‘Hence, the failure of BPA to pro-
duce reproducible adverse effects via a relevant route of exposure,
coupledwith the lackof robustnessof themanyof the lowdose stud-
ies (sample size, dose range, statistical analyses and experimental
design, GLP) and the inability to reproduce many of these effects of
any adverse effect, strains the credibility of some of these study re-
sults’’ (Chapin et al., 2008).
Also in 2008, NTP published the NTP-CERHRMonograph on BPA,
which provided the NTP’s scientiﬁc basis for its conclusion of (1)
‘‘SomeConcern’’ for effectson thebrain, behavior, andprostategland
in fetuses, infants, and children at current human exposures to BPA;
and (2) ‘‘minimal concern’’ for effects on themammary gland and an
earlier age for puberty for females in fetuses, infants, and children at
current human exposures to BPA. There are distinct differences in
the Panel’s report and the NTPMonograph on BPA (Expert Scientiﬁc
Panels and other advisory groups act only in an ‘‘advisory capacity’’
to US federal agencies). The NTP-CERHRmonograph discussed deﬁ-
ciencies in the published literature and identiﬁed areas requiring
more research, noting study designs andmethodologies considered
appropriate to address these areas. Speciﬁcally, NTP-CERHR sug-
gested conducting ‘‘low dose’’ animal studies (<5 mg BPA/kg bw/
day) using oral dosing that evaluate developmental effects in the
areas of neural and behavior alterations, lesions in the prostate
and mammary glands, altered prostate and urinary tract develop-
ment, andearlyonsetofpuberty.NTP-CERHRnoted thatmanyscien-
tiﬁc studies ‘‘were designed not as toxicology studies but rather to
probe very speciﬁc experimental questions, and their results are
not always easily interpreted with regard to how they contribute
to the weight-of-evidence for human health risks’’ (NTP, 2008).
NTP also noted study design and analysis factors, such as animal
models, routes of administration, and statistical data analysismeth-
ods that they would like to see used in future studies to address to
their concerns. The impact of theNTP-CERHRMonograph on BPA re-
search has been signiﬁcant, with NIEHS itself funding $30 million
dollars of additional BPA research through extramural granting pro-
grams, and the FDAcommitting to conductingadditional risk assess-
ments and supporting additional BPA research. The NTP-CERHR
concerns regarding study design and methodology are listed in
Table 1.
Finally, the NTP discussed areas of difﬁculty in interpreting
study results. These are listed in Table 2.9. Evaluation of recent studies regarding pharmacokinetics, and
brain and behavioral effects
Since the NTP-CERHR report (NTP, 2008), hundreds of studies
evaluating the health effects of BPA have been published. We sum-
marize the recently published scientiﬁc literature regarding
Table 2
NTP concerns regarding interpretation of study results.
Insufﬁcient replication of studies by independent investigators
Suitability of various experimental approaches
Relevance of the speciﬁc animal model
Incomplete understanding of whether a reported effect is adverse
Does the effect persist in life or does it manifest as a clear health effect later in
time?
Incomplete understanding of the metabolism and pharmacokinetics of BPA in
humans and animals
Incomplete understanding of the shape of the dose response curve
Are the results biologically plausible?
Are results across studies consistent?
NTP (2008).
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pers studying BPA neurobehavioral effects that were identiﬁed by
EFSA and BfR as being valid for use in risk assessment, to determine
whether they address the NTP-CERHR suggestions for study de-
signs and methodologies (BfR, 2008; EFSA, 2012).
9.1. Pharmacokinetics and metabolism
Understanding the serum levels associated with typical dietary
exposure and the differences in pharmacokinetics and metabolism
between humans and laboratory animal species is critical for prop-
er interpretation of toxicology studies. BPA is metabolized mainly
through conjugation to form the glucuronide metabolite (BPA glu-
curonide), which lacks estrogenic activity (Calafat, 2011; Matthews
et al., 2001). Humans and laboratory animals (rats, mice, and NHP)
form the glucuronide as the primary metabolite. Adult rats or mice
rapidly metabolize orally-administered BPA to the glucuronide,
which is then eliminated primarily via the bile (Doerge et al.,
2010b). NHP and humans also rapidly metabolize orally-adminis-
tered BPA to the glucuronide; however, it is eliminated primarily
via the urine (Doerge et al., 2010a). Recent metabolism and phar-
macokinetic studies are discussed in detail below.
9.1.1. Teeguarden et al., 2011; Völkel et al., 2002
Two pharmacokinetic studies (Teeguarden et al., 2011; Völkel
et al., 2002) have been conducted in humans using doses of
approximately 70 lg/kg bw and 0.27 lg/kg bw (estimated dose),
respectively. The Völkel study had a 10 nM (2.3 ng/mL) detection
limit and the Teeguarden study had a detection limit of 1.3 nM
(0.3 ng/mL). The Teeguarden study was conducted in volunteers
who consumed a diet ‘‘enriched in canned food items likely to be
signiﬁcant dietary sources of BPA’’ (Teeguarden et al., 2011), and
was intended to determine BPA aglycone serum levels in people
with a high dietary BPA intake. Neither the Völkel nor the Teeguar-
den studies were able to detect BPA aglycone in serum, indicating
that BPA aglycone was either not present or that concentrations
were below their respective detection limits.
In addition, there are several published reports of serum BPA
aglycone levels from single samples obtained from various popula-
tions. Many of these have found that levels are below detectable
limits; however some have detected levels up to 1–2 ng/mL (infor-
mation compiled from the scientiﬁc literature by Vandenberg et al.,
2010). Since these serum levels are higher than what would be ex-
pected based on the studies by the Völkel and Teeguarden studies,
some scientists have suggested that these reported levels may be
due to undetected contamination of laboratory equipment with
BPA, since BPA is present in common materials used during sample
processing and analysis (Ye et al., in press).
9.1.2. Taylor et al., 2011
Taylor et al. (2011) conducted pharmacokinetic studies in adult
female CD-1 mice and adult female rhesus monkeys. Monkeyswere fed deuterated BPA (dBPA) at a dose of 400 lg/kg bw/day in
food for 7 days. Blood samples were collected on the ﬁrst and sev-
enth days for 24 h. Mice were administered 400 lg/kg bw/day of
tritium-labeled BPA (3H-BPA) orally, and blood was collected for
24 h. In monkeys, the maximum BPA aglycone level (Cmax) oc-
curred at 1 h after dosing and was 4 ng/mL. This level declined over
24 h, and there was no bioaccumulation of BPA. In mice, the Cmax
also occurred at 1 h and was 3.2 ng/mL.
The authors then compared the levels of conjugated BPA in fe-
male mice and monkeys to those found in human females who
had a single oral dose of 5 mg dBPA (which, based on the body
weight of the subjects, averaged 69.3 lg/kg bw) in Völkel et al.
study (2002). The authors found that BPA glucuronide conjugate
pharmacokinetics were similar in female monkeys, mice and hu-
mans. Since Völkel et al. were unable to detect BPA aglycone in hu-
mans with a detection limit of 10 nM (2.3 ng/ml), no comparison
could be made by Taylor et al. between human female BPA agly-
cone levels and those in mice and monkeys.
The authors also compared the 24-h average BPA aglycone lev-
els in mice and monkeys of 0.5 ng/ml after a 400 lg/kg bw oral
dose with studies that have reported levels in humans up to
approximately 2 ng/ml (see compilation by Vandenberg et al.,
2010) and concluded that ‘‘total daily human exposure . . . is much
higher than previously assumed.’’ This conclusion relies heavily
on the reports of human BPA aglycone levels from single samples
in various population groups. Since these reports are not studies
in which humans were dosed with dBPA, the accuracy of these lev-
els is unclear. An ongoing human pharmacokinetic study by NIEHS/
FDA using dBPA, described below, should provide further informa-
tion to clarify the blood levels of BPA aglycone achieved in humans
following oral dosing.
9.1.3. Doerge et al. (2010a,b, 2011b)
Doerge et al. conducted a series of pharmacokinetic studies in
neonatal and adult CD-1 mice, Sprague–Dawley rats and rhesus
monkeys (Doerge et al., 2010a,b, and 2011b). The authors adminis-
tered 100 lg BPA/kg bw in DMSO and water using both the intra-
venous (i.v.) and oral routes of exposure to allow comparison
between species and routes of exposure. The results show that ser-
um BPA aglycone levels are approximately an order of magnitude
lower in newborn rhesus monkeys compared to CD-1 mice and
Sprague–Dawley rats following the equal oral doses. In addition,
for monkeys, the difference between the Cmax concentration for
newborns and adults is about 2-fold, whereas, for mice and rats,
the difference is about 10-fold (Fig. 6 in Doerge et al., 2011b), with
the newborns having the higher levels in both species.
Furthermore, the percentage of the unconjugated BPA (agly-
cone) in the serum of monkeys following oral dosing is less than
1% of the total BPA for both neonates and adults (Doerge et al.,
2010a). In comparison, the unconjugated BPA in neonatal mice
and rats is substantially higher than the adult (8–20 times higher
in rats and mice, respectively; Fig. 7 in Doerge et al., 2011b).
Doerge et al. (2011b) note: ‘‘[M]any of the human UGT 1A and
2B isoforms catalyzing glucuronidation of BPA . . .are homologous
with those in monkeys . . .and the known ontogeny of human
UGT isoforms . . .predicts that glucuronidation of BPA is well-devel-
oped at birth in primates vs. the overall immaturity of rodents at
birth reﬂected by reduced UGT activity . . .These observations are
consistent with the approximately order of magnitude lower inter-
nal exposures to the unconjugated form of BPA following oral
administration seen in neonatal monkeys relative to neonatal
rodents.’’
9.1.4. Fisher et al., 2011
Fisher et al. (2011) developed physiologically-based pharmaco-
kinetic (PBPK) models for i.v. and oral administration of BPA to
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et al. (2010a,b, 2011b). The authors also ﬁt their model to the mon-
key data published by Taylor et al. (2011), and created a separate
set of ‘‘revised model parameters’’ for this data.
In order to ﬁt the model to the published monkey data, the
authors assumed some renal tubular reabsorption of BPA conju-
gates occurs (based on the studies of Gotoh et al., 2002 and Jemnitz
et al., 2010) and that metabolism of BPA to conjugates occurs in the
small intestine (based on the studies of Audebert et al., 2011 and
Mazur et al., 2010) as well as the liver. According to the authors,
these two assumptions allowed for a better ﬁt of the model to
the data, compared to including enterohepatic recirculation in
the model.
The authors then simulated BPA aglycone and conjugate phar-
macokinetics for adult humans using human physiological param-
eters and a dose of 5 mg of BPA in their original model and the
model with the ‘‘revised model parameters’’ obtained by using data
from Taylor et al. (2011) study. The resulting plasma levels were
compared to the human BPA pharmacokinetic data obtained by
Völkel et al. (2002) following administration of 5 mg BPA to hu-
mans. (Völkel and colleagues were unable to detect BPA aglycone
in plasma samples with a detection limit of 10 nM [2.3 ng/ml],
however, they were able to detect BPA conjugates). Both the origi-
nal model and the model with revised parameters predicted that
BPA aglycone levels in humans following a dose of 5 mg BPA (Völ-
kel et al. 2002) would be below a 10 nM detection limit, as was
found in the Völkel et al. (2002) study.
9.1.5. Doerge et al., 2011a
Doerge et al. (2011a) administered dBPA at a dose of 100 lg/
kg bw to pregnant SD rats by either the oral or i.v. routes ofTable 3
Comparison of BPA aglycone maximum serum levels, percentage unconjugated and elimin
Reference Dose
(lg/kg BW)
Route Species, sex Age of
animal
(N)
Cmaxa
(nM)
C
(n
Taylor et al.
(2011)
400 Oral CD-1 mice, female Adult, N
approx. 40b
3
Rhesus monkey,
female
Adult, N = 11 3
Doerge et al.
(2011b)
100 Oral CD-1 mice, males
and females
Adult, N = 84 0.18 0
PND 3, N = 24 34 7
PND 10, N = 24 7.4 1
PND 21, N = 24 1.1 0
Doerge et al.
(2010a)
100 Oral Rhesus monkeys,
female
Adult, N = 4 0.84 0
Rhesus monkeys,
males and females
PND 5, N = 6 2 0
Rhesus monkeys,
males and females
PND 35, N = 6 1.1 0
Rhesus monkeys,
males and females
PND 70, N = 6 1.5 0
Doerge et al.
(2010b)
100 Oral S–D rats, female Adult, N = 5 0.39 0
S–D rats, males
and females
PND 3, N = 24 29 6
PND 10, N = 24 6.7 1
PND 21, N = 24 0.7 0
Prins et al.
(2011)
10 Oral S–D rats, males PND 3, N = 90 1.13 0
a Cmax = Maximum serum concentration.
b Five or six animals used per blood collection time point, with blood collected sevenexposure. Blood samples, fetal tissues and amniotic ﬂuid were col-
lected for analysis. Whereas BPA administered i.v. to Sprague–
Dawley rats resulted in measurable amounts of BPA aglycone in
the fetus, orally administered BPA at the same dose level did not
produce measurable levels of BPA in the fetus, with detection lim-
its of 0.2 nM (0.045 ng/ml in serum, and 0.4 pmol/g (0.00009 ng/g)
tissue (Doerge et al., 2011a). This is an important observation since
the vast majority of humans are exposed to BPA via the oral route
(WHO, 2011). In addition, amniotic ﬂuid levels of BPA aglycone
were at or below maternal serum levels.
9.1.6. Summary of pharmacokinetic studies
Table 3 below compares the maximum serum concentration of
BPA aglycone (Cmax), the percentage unconjugated in the serum,
and the elimination half-life reported in studies using various ani-
mal species. The table reports the dose, the Cmax as listed in the
paper, and the Cmax corrected to a 100 lg/kg bw dose, for pur-
poses of comparison. Cmax values corrected to a 100 lg/kg bw
dose ranged from 0.041 ng/mL in adult CD-1 mice to 7.7 ng/mL
in post-natal day (PND) 3 CD-1 mice. It is clear from the table that
neonatal rats and mice have much higher Cmax values, when cor-
rected for dose, than adults of the same species. In addition, neona-
tal rats and mice have much higher Cmax values than neonatal and
adult monkeys, when corrected for dose.
Of note, a study of human BPA pharmacokinetics using a dose of
100 lg/kg bw deuterated BPA is expected to be completed in the
near future by NIEHS/FDA (Patterson et al., 2013). The results of
this study, utilizing deuterated BPA, will provide insight regarding
BPA metabolism and distribution in humans after oral exposure.
Upon completion of this study, pharmacokinetic data will be avail-
able for mice, rats, NHP and humans for comparative modeling,ation half-life reported in the scientiﬁc literature.
max
g/mL)
Cmax (ng/mL)
corrected to
100 lg/kg bw
dose
Unconjugated
Elimination
half-life (h)
%
Unconjugated
at Cmax
Comments
.28 0.82 0.8 % Unconjugated
determined at a
100,000 lg/kg bw
dose
.95 0.9875 2.6
.041 0.041 0.63 0.45
.7 7.7 5.9 19.0
.7 1.7 3 5.3
.25 0.25 0.2 3.9
.19 0.19 0.39 0.14
.46 0.46 2 0.29
.25 0.25 1.7 0.20
.34 0.34 1.5 0.60
.089 0.089 3 0.53
.6 6.6 8.5 6.52
.5 1.5 4 3.06
.159 0.159 1.9 0.38
.26 2.6 Not
determined
27 Prins et al. (2011)
reported %
unconjugated as
29%, 21% and 31%
at 0.5, 1 and 2 h,
respectively. 27 is
the average of
these values
times.
Table 4
NTP-CERHR concerns regarding neural and behavioral studies in animals.
Neural and behavioral alterations
Use of appropriate route of exposure
Are the ﬁndings relevant to humans given the brain differences between
humans and animals?
Is the body of literature consistent in the ﬁndings?
Did the authors assess the functional impacts of structural changes?
Were the changes transitory or permanent?
Did the authors control for the differences in circulating levels of sex
hormones at the time of testing?
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mation that may be able to reduce uncertainties in future safety
analysis. In addition, a dBPA pharmacokinetic study in pregnant
NHPs will be published in the near future (Patterson et al., 2013).
9.2. Neural and behavioral alterations
The NTP-CERHR monograph (2008) noted that studies assessing
the neurological effects of BPA to date were difﬁcult to interpret for
health assessment purposes. For example, some studies adminis-
tered BPA directly into the brain, rather than using the oral route
of exposure, the relevant route for humans from food consumption,
and some have found changes in the cellular composition of animal
brain structures that humans do not have, making extrapolation to
humans difﬁcult or impossible. In addition, the NTP-CERHR had
other methodological concerns, which are listed in Table 4 below.
Regarding studies of neural and behavioral alterations, there are
two studies using the oral route of exposure that address NTP’s
areas of concern, Ryan et al. (2010) and Stump et al. (2010). Both
of these were published since the NTP (2008) report.
9.2.1. Ryan et al. 2010
Ryan et al. (2010) orally dosed adult female Long Evans (LE) rats
with BPA at doses of 0, 2, 20 or 200 lg/kg bw/day on day 7 of ges-
tation through PND 18. As a positive control, the authors also orally
dosed groups of female rats with ethinyl estradiol (EE) at doses
ranging from 0.05 to 50 lg/kg bw/day during the same timeframe
of pregnancy and lactation.
The authors evaluated onset of puberty, fertility, and anatomy
of the female offspring. They also examined sexually dimorphic
behavior using behavioral tests in rats speciﬁc for hormonally-
mediated effects: sweet (saccharin) preference and lordosis (BfR,
2010).
BPA-dosed rats were not signiﬁcantly different in any study
endpoint from vehicle-treated controls. In contrast, EE-dosed rats
had increased anogenital distance, decreased body weight of pups
on PND 2, reduced F1 fertility and F2 litter sizes, and malforma-
tions of the external genitalia at a dose of 5 lg/kg bw/day. In addi-
tion, the female EE-dosed pups had an accelerated time of vaginal
opening. The F1 females had indications of defeminization of the
CNS, as evidenced by a reduced (male-like) saccharin preference
at a dose of 5 lg/kg bw/day, and an absence of lordosis at a dose
of 15 lg/kg bw/day.
This study addressed the following NTP concerns: (1) it used an
oral exposure route with ‘‘low’’ doses of BPA (2–200 lg/kg bw/
day); (2) animals were dosed at the gestational time of reproduc-
tive organ development and the time during lactation when hor-
monal imprinting of behaviors occurs; (3) an adequate number
of dams were used (6–38 per group); (3) an appropriate animal
model was used, as evidenced by the effects seen in the positive
control group; (4) statistical analysis used the litter as the experi-
mental unit; (5) the authors used a range of BPA doses that were
relevant to estimated human exposures; (6) the positive controlsexhibited a dose–response for estrogenic effects; (7) the authors
controlled for variations in the circulating levels of sex hormones
at times of testing by ovarectomizing the females and administer-
ing replacement hormones at a controlled dose; and (8) the ani-
mals were tested for behavioral (functional) impacts using tests
(sweetness preference and lordosis) that the authors validated in
LE rats in a pilot study.
EFSA (2010) evaluated the Ryan study and found the study va-
lid. They stated ‘‘The size of the experimental groups was adequate
and the statistical analysis of the data was appropriate. The inclu-
sion of the estrogenic reference compound EE at several doses
demonstrates the sensitivity of the test animals (P1.5 lg/kg bw/
day) and of the methods to detect estrogen-related toxicity. . .
The dosage levels of BPA used by Howdeshell et al. (2008) and
Ryan et al. (2010a) are in line with those used in ‘‘low-dose’’ BPA
studies with rats, with the lowest dose (2 lg/kg bw/day) being in
the same range or below the estimated average intake of the Euro-
pean population including infants, children and adults (1.5–13 lg/
kg bw/day) (EFSA, 2006).... Overall, the [EFSA] Panel considered the
experimental design and the performance of the study as va-
lid. . .The latter study (Ryan et al., 2010) also addressed speciﬁcally
the impact of BPA on the sexually dimorphic behavior of female
rats, i.e. sweet preference and lordosis behavior, which were
clearly affected by ethinylestradiol treatment, but not by any BPA
dose. Therefore, the Panel concludes that the study results did
not indicate any low-dose effects of BPA on the development of
sexually dimorphic behavior in female rats.’’
9.2.2. Stump et al. 2010
Stump et al. (2010) is a GLP-compliant study that evaluated
functional and morphological nervous system effects following
exposure to BPA during gestation and lactation. Female Sprague
Dawley rats were fed chow to which BPA had been added at levels
of 0, 0.15, 1.5, 75, 750 and 2250 ppm. This resulted in estimated
doses (based on feed consumption) of 0, 0.01, 0.12, 5.85, 56.4
and 164 mg BPA/kg bw/d during gestation, and to 0, 0.03, 0.25,
13.1, 129 and 410 mg BPA/kg bw/d during lactation. Thus, this
study included groups with ‘‘low’’ BPA doses. Females were fed
BPA from gestational day 0 until PND 21, when the pups were
weaned, and the dams sacriﬁced. Pups were assigned to subset
groups A, B, C (1 pup per sex per liter). Group A was given detailed
clinical examinations, evaluated for developmental landmarks
(balanopreputial separation and vaginal patency), auditory startle
response, motor activity, and, starting on PND 62, for learning
and memory. Group B was evaluated for learning and memory
starting on PND 22. Group C was necropsied on PND 21, and brain
weight and morphometric and neuropathological evaluations were
determined.
The BPA-treated dams in the two highest dose groups had de-
creased maternal body weight gain (9.5% for the 56.4 mg/kg bw/
day group and 22.4% for the 164 mg/kg bw/day group). There were
no effects on gestation length or parturition, number of pups born,
live litter size, sex ratio, postnatal viability, and the BPA treated
pups had no differences in surface righting response compared to
untreated controls. The authors found that the NOAEL for develop-
mental neurotoxicity was 2250 ppm BPA added to food (the high-
est dose tested), which corresponds to a dose of approximately 164
and 410 mg/kg bw/day during the periods of gestation and lacta-
tion, respectively.
For evaluation of motor activity, the authors provided historical
control data and used haloperidol, nicotine and amphetamine as a
positive control. The results showed that BPA exposed offspring
had no differences in the pattern of activity counts. Regarding
the developmental landmarks of balanopreputial separation and
vaginal patency, there was no difference between the BPA-treated
pups and untreated controls. For evaluation of the auditory startle
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used chlorpromazine, nicotine, amphetamine or 8-hydroxy-N,N-
dipropyl-2-aminotetralin as positive controls. No differences were
found in the BPA-exposed offspring compared to untreated
controls.
For evaluation of memory and learning, the authors used the
Biel maze test (swimming test). The authors reported some spo-
radic differences between groups and stated ‘‘all statistically signif-
icant differences noted were considered spurious and not BPA
related because they did not occur consistently between or within
testing periods, did not demonstrate any evidence of a dose-related
trend, and/or were associated with atypical control responses’’
(Stump et al., 2010).
The authors concluded that there was no evidence for BPA
neurotoxicity, and established a No Observable Adverse Effect Le-
vel (NOAEL) for developmental neurotoxicity of 2250 ppm in feed
(the highest dose tested), which corresponds to 164 and 410 mg/
kg bw/day during gestation and lactation, respectively.
The German Federal Institute for Risk Assessment (BfR) evalu-
ated this study and stated ‘‘for the tests on learning and memory
historical control data as well as data on the test performance
and validity – as normally required by the test guideline – were
provided with the test report. Data obtained with scopolamine
served as a positive control for prolonging latency and increasing
erroneous trials in the Biel maze. The swimming ability on the ﬁrst
day of testing was similar across all groups (BPA exposed and non-
exposed) for either age. Also, the number of errors in escaping the
maze via either path as well as after reverse sequence did not re-
veal signiﬁcant differences across groups at either age tested.’’(BfR,
2010)
However EFSA’s assessment found ‘‘that the Biel maze test as
performed by Stump et al. does not have the potential to demon-
strate equivalence of BPA compared to a control. . .. Based on the
re-analysis the Panel considered that no conclusion can be drawn
from this study on the effect of BPA on learning and memory
behavior due to large variability in the data.’’ (EFSA, 2010)
Stump et al. also noted some ﬁndings that they state are ‘‘inci-
dental’’. They report: ‘‘Incidental ﬁndings in the BPA-exposed
groups included the following: on PND 11 only, a total of six pups
(two animals from the 750-ppm group and four from the 2250-
ppm group) exhibited irregular jerking movements of limbs, head,
and/or body and/or jumping with all four feet in the air. These clo-
nic movements were recorded as ‘‘convulsions’’ and/or ‘‘popcorn
seizures.’’ The incidence of these ﬁndings was not statistically sig-
niﬁcant and occurred during the same period where statistically
signiﬁcantly reduced mean pup body weight gains were noted
(PNDs 7–14) in the 750- and 2250-ppm groups. These ﬁndings
were not observed at any other age. For these six animals, there
were no remarkable ﬁndings in the other end points examined as
part of the detailed clinical observations. The incidence of these
ﬁndings in the historical control database at PND 11 is 2 of 244 fe-
males and 0 of 243 males. Since the incidence of these ﬁndings in
the present study was greater than the historical control incidence,
a focused follow up study was conducted at 2250 ppm BPA to
determine reproducibility and, if appropriate, to further character-
ize these ﬁndings. Similar effects were noted on body weight in the
dams and offspring; however, no clonic movements were observed
on PND 11 in this robust follow-up study; therefore, the initial
observations were not considered being treatment related’’ (Stump
et al., 2010).
EFSA’s evaluation of this ﬁnding states ‘‘the Panel considered
the toxicological signiﬁcance of this observation as being very lim-
ited because convulsions and seizures were not seen in any other
occasion during the study, and could not be reproduced in a fol-
low-up study with animals exposed to 0 or 2250 mg/kg feed
according to the same study design... Also, convulsions or ‘‘popcornseizures’’ or similar clonic movements have not been reported in
any other study on BPA, including the available reproductive toxic-
ity and developmental neurotoxicity studies, as summarized in
EFSA previous evaluations, in the EU-RAR and its addendum or
the NTP-CERHR Monograph.’’
BfR reviewed the incidental ﬁnding and determined that since
‘‘the ﬁndings from the main study had not been reproduced in
the follow-up study, the behavioral abnormalities as observed in
six animals on PND 11 in the study were not considered to be sub-
stance related’’ (BfR, 2010).
This study addressed the following NTP concerns: (1) it used an
oral exposure route with ‘‘low’’ doses of BPA; (2) animals were
dosed at the gestational time of reproductive organ development
and the time during lactation when hormonal imprinting of behav-
iors occurs; (3) an adequate number of dams were used (12 per
group); (4) an appropriate animal model was used, as there is evi-
dence that SD rats are responsive to the effects of estrogen (EFSA,
2010); (5) statistical analysis used the litter as the experimental
unit; (6) the authors used ‘‘low’’ doses of BPA that are relevant to
estimated human exposures; and (7) the animals were tested for
behavioral (functional) impacts using tests (auditory startle re-
sponse and learning and memory) with positive controls.
Regarding their overall conclusions for Stump et al., 2010 study,
EFSA states ‘‘The CEF Panel considers this treatment schedule as
relevant to human exposure in utero and via either breastfeeding
or infant bottle feeding (in this study the estimated exposure of
rat pups to BPA is ca. 30 times higher than that of bottle-fed in-
fants).’’ EFSA notes ‘‘The study by Stump covers motor activity,
learning and memory (spatial behavior), auditory startle response,
brain histopathology and morphology. The study does not cover
some speciﬁc aspects of learning and memory (i.e. avoidance learn-
ing, schedule-controlled behavior, and impulsiveness), anxiety-re-
lated behavior or sexual dimorphic behavior, but this does not
invalidate the study. No treatment-related changes were observed
in motor activity tests, auditory startle response or brain histopa-
thology and morphology.’’
BfR states ‘‘The study of Stump et al. (2010) meets the require-
ments of the neurodevelopmental toxicity study as requested by
the Norwegian Food Safety Authority consequently to their re-
evaluation of the four crucial non-regulatory studies that had been
considered as valid and relevant for quantitative risk assessment
by three Nordic EU countries during the EU risk assessment of
BPA. The test followed a guideline-conform standard protocol
using oral administration via diet (an application route of human
relevance) and addressed relevant end-points for the detection of
a speciﬁc toxic potential harmful to brain and/or neurobehavioural
development. With this protocol (OECD 426, adopted in 2007),
which is the counterpart of the US EPA guideline OPPTS
870.6300, used in the US and in Canada for the approval of pesti-
cide active substances, more than 130 test reports and a compre-
hensive retrospective evaluation are available. . . Thus, this test
protocol has already been applied routinely and broad experience
has been gained with it.’’
BfR (2010) states ‘‘Except the effects observed on body weight
gain at the two higher dietary concentrations no further effects
had been observed in this test. The testing of standard endpoints
able to detect effects on the brain and/or neurological and behav-
ioral development, however, did not reveal any impairment at very
low exposure levels and no impairments were seen at exposure
levels that had been associated with effects on body weight. Thus
the results of this study do not provide evidence for neurodevelop-
mental toxicity of BPA at the exposure levels that had been tested.’’
Despite some critiques pointing to study limitations; e.g., low
doses and issues with caging materials and phytoestrogens in the
diet – (Ryan et al.); no reference estrogenic standard to measure
test sensitivity - (Stump et al.), there is a general regulatory
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latory merit (FSANZ, 2012; EFSA, 2012).10. Discussion
BPA is widespread worldwide and has been used for over
50 years as a component of polycarbonate plastic epoxy resins that
are, among other uses, used to coat metal food and beverage cans.
Low levels of BPA can leach from the food containers into foods,
and BPA can be found in trace levels in human urine (Lakind and
Naiman, 2011). Both the RfD and the TDI of 50 lg/kg bw/day are
approximately 33 times higher than the 95th percentile BPA intake
level for adults of 1.5 lg/kg bw/day, estimated byWHO (2011), 225
times greater than the 95th percentile daily BPA intake of 0.223 lg/
kg bw/day for individuals aged 6–60 years estimated by Lakind and
Naiman (2011), and approximately 20 times the FDA estimation of
the BPA intake in infants of 2.42 lg/kg bw/day FDA (2008).
While numerous animal studies have been conducted in the last
few years, due to study designs and methodological problems, it is
not clear how some of those studies apply to human risk assess-
ment. In addition, there are pharmacokinetic differences between
neonatal and adult laboratory animals and humans, which must
be accounted for when evaluating potential health effects of BPA.
For example, neonatal rats or mice do not metabolize BPA as efﬁ-
ciently as adult animals, resulting in higher blood levels of BPA
in neonates compared to adults, and due to its rapid metabolism
and excretion, BPA does not bio-accumulate (Doerge et al.,
2010a; 2011a,b). In contrast to rats and mice, minimal pharmaco-
kinetic differences were seen comparing fetal, neonatal and adult
NHPs (Doerge et al., 2010a; 2011a,b). Also, in contrast to mice
and rats, BPA-glucuronide is excreted predominantly via the urine
rather than the feces in NHP and humans, does not undergo signif-
icant enterohepatic recirculation, and is rapidly eliminated from
the body (Doerge et al., 2010a; 2011a,b). Furthermore, in rats
and mice, BPA glucuronide is excreted predominantly via the bile
into the feces, where there is evidence that it undergoes enterohe-
patic re-circulation. This results in re-generation of the BPA agly-
cone, which is reabsorbed into the blood stream, and prolongs
the exposure to BPA. Thus, when administered the same dose, rats
will have a longer exposure compared to NHPs.
In pregnant Sprague–Dawley rats administered BPA orally,
maternal gut and liver metabolism rapidly converts BPA aglycone
(active) to the inactive BPA-glucuronide via ﬁrst pass phase II
metabolism. This signiﬁcantly reduces the amount of BPA aglycone
that enters the circulation and decreases that amount that could
reach the fetus (Doerge et al., 2011a), although the maternal rat
also showed evidence of enterohepatic recirculation through reab-
sorption of BPA from bile, which would prolong the exposure to
BPA (Doerge et al., 2011a). Of note, when rats are dosed intrave-
nously, BPA aglycone concentrations in the blood stream are great-
er than with oral dosing since it does not go through ﬁrst-pass
metabolism.
The rat fetus also has the capacity to convert BPA aglycone to
BPA glucuronide; this capacity increases as the fetus matures in
utero achieving near maternal capacity at term (Doerge et al.,
2011a). Pharmacokinetic and metabolism research conducted in
pregnant NHP is expected to be published and this will provide
additional information (Patterson et al., 2013).
Due to pharmacokinetic and metabolic differences, there is the
potential for rats and mice, especially neonatal rats and mice, to
have a higher exposure to BPA aglycone than NHP and humans;
thus, studies in postnatal rats or mice may over-predict adverse
outcomes in NHP and humans (Doerge et al., 2010a). Extrapolation
of adverse ﬁndings from rats and/or mice to humans may not be
appropriate or straightforward.There are two recent studies assessing BPA’s effect on the brain
and behavior after oral administration; both of these studies ap-
pear to meet NTP-CERHR concerns regarding study design and
methodology. Ryan et al. (2010) evaluated sexually dimorphic
behavior, onset of puberty, fertility, and anatomy of female LE rats
following in utero and lactational exposure and concluded that BPA
(up to 200 lg/kg bw/day) had no effects. Stump et al. (2010) eval-
uated functional and morphological nervous system effects follow-
ing exposure to BPA during gestation and lactation in SD rats, and
found no evidence for BPA developmental neurotoxicity.
EFSA and BfR evaluated both Ryan et al. (2010) and Stump et al.
(2010) studies and found theywere both valid for use in risk assess-
ments. EFSA concluded: ‘‘Overall, based on the comprehensive eval-
uation of recent human and animal toxicity data, the Panel
concluded that no new study could be identiﬁed, which would call
for a revision of the current TDI of 0.05 mg/kg bw/day. This TDI is
based on the NOAEL of 5 mg/kg bw/day from a multi-generation
reproductive toxicity study in rats, and the application of an uncer-
tainty factor of 100, which is regarded as conservative based on all
information on BPA toxicokinetics. . . The Panel considers that the
valid studies do not raise concern regarding reproductive and
developmental toxicity of BPA at doses lower than 5 mg/kg bw/
day. . . The Panel does not consider the currently available data as
convincing evidence of neurobehavioural toxicity of BPA’’ (EFSA,
2010). BfR concluded ‘‘[T]he results of the two studies do not sub-
stantiate the concerns for a speciﬁc toxic potential of bisphenol A
adverse to neurological and behavioral development’’ (BfR, 2010).11. Conclusions
This paper discusses some of the controversial issues surround-
ing BPA, summarizes the current regulatory status of BPA, reviews
recent pharmacokinetic studies, and describes ongoing and
planned research on the effects of BPA. In addition, we evaluate
two papers studying BPA neurobehavioral effects, identiﬁed by
EFSA and BfR as being valid for use in risk assessment, to determine
whether they address the NTP-CERHR suggestions for study de-
signs and methodologies.
Signiﬁcant progress has been made in evaluating the pharmaco-
kinetic similarities and differences in rats, mice and NHP. A recent
human study has assessed the fate of BPA after consumption of
BPA-containing meals, and a currently-ongoing human pharmaco-
kinetic study using deuterated BPA will facilitate direct compari-
sons of BPA metabolism and pharmacokinetic parameters to that
of mice, rats and NHP at doses consistent with known human
BPA exposures. The results are anticipated to provide information
regarding the potential for rats and mice, especially neonatal rats
and mice, to have greater exposure to BPA aglycone compared to
NHP and humans. Two studies referenced in this paper assessing
BPA’s neurobehavioral effects, which incorporated NTP-CERHR
suggestions for study design and methodologies, did not ﬁnd neu-
rological or behavioral effects at low dose BPA exposures. At this
time, EFSA, BfR, FDA, Health Canada, German Society of Toxicology,
and the Japanese National Institute of Advanced Industrial Science
and Technology (AIST) all support the use of BPA in food contact
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